We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 12 april 2018

Prostate Cancer and Prostatic Diseases - Table of Contents alert Volume 21 Issue 1

If you are unable to see the message below, click here to view.
Prostate Cancer and Prostatic Diseases
 
TABLE OF CONTENTS

Volume 21, Issue 1

In this issue
Editorial
Review Article
Article
Also new
AOP
 

Editorial

20 years–A retrospective of prostate cancer and prostatic diseases

Stephen J Freedland

Prostate Cancer and Prostatic Diseases 2017 21 :1 - 3; December 19, 2017; 10.1038/s41391-017-0025-6

 

Abstract | Full Text

Review Article

The use of PET/CT in prostate cancer

Roger Li, Gregory C. Ravizzini, Michael A. Gorin, Tobias Maurer, Matthias Eiber et al.

Prostate Cancer and Prostatic Diseases 2017 21 :4 - 21; December 11, 2017; 10.1038/s41391-017-0007-8

 

Abstract | Full Text

The molecular biology of prostate cancer: current understanding and clinical implications

Jason Gandhi, Adil Afridi, Sohrab Vatsia, Gargi Joshi, Gunjan Joshi et al.

Prostate Cancer and Prostatic Diseases 2017 21 :22 - 36; December 27, 2017; 10.1038/s41391-017-0023-8

 

Abstract | Full Text

Current approaches to incorporation of radium-223 in clinical practice

Chris Parker, Axel Heidenreich, Sten Nilsson & Neal Shore

Prostate Cancer and Prostatic Diseases 2018 21 :37 - 47; January 03, 2018; 10.1038/s41391-017-0020-y

 

Abstract | Full Text

Germline BRCA mutation in male carriers-ripe for precision oncology?

Ricardo Romão Nazário Leão, Aryeh Joshua Price & Robert James Hamilton

Prostate Cancer and Prostatic Diseases 2017 21 :48 - 56; December 14, 2017; 10.1038/s41391-017-0018-5

 

Abstract | Full Text

Article

Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer

Tobias Nordström, Olof Akre, Markus Aly, Henrik Grönberg & Martin Eklund

Prostate Cancer and Prostatic Diseases 2017 21 :57 - 63; December 19, 2017; 10.1038/s41391-017-0024-7

 

Abstract | Full Text

Preoperative prostate health index predicts poor pathologic outcomes of radical prostatectomy in patients with biopsy-detected low-risk patients prostate cancer: results from a Chinese prospective cohort

Bo Tang, Cheng-Tao Han, Xiao-Lin Lu, Fang-Ning Wan, Cui-Zhu Zhang et al.

Prostate Cancer and Prostatic Diseases 2017 21 :64 - 70; December 06, 2017; 10.1038/s41391-017-0002-0

 

Abstract | Full Text

Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged=50 years: a population-based study

Raisa S. Pompe, Ariane Smith, Marco Bandini, Michele Marchioni, Tristan Martel et al.

Prostate Cancer and Prostatic Diseases 2018 21 :71 - 77; January 16, 2018; 10.1038/s41391-017-0006-9

 

Abstract | Full Text

Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting

Jay White, B. Vittal Shenoy, Ronald F. Tutrone, Lawrence I. Karsh, Daniel R. Saltzstein et al.

Prostate Cancer and Prostatic Diseases 2017 21 :78 - 84; November 20, 2017; 10.1038/s41391-017-0008-7

 

Abstract | Full Text

Indication to pelvic lymph nodes dissection for prostate cancer: the role of multiparametric magnetic resonance imaging when the risk of lymph nodes invasion according to Briganti updated nomogram is <5%

Francesco Porpiglia, Matteo Manfredi, Fabrizio Mele, Riccardo Bertolo, Enrico Bollito et al.

Prostate Cancer and Prostatic Diseases 2018 21 :85 - 91; February 22, 2018; 10.1038/s41391-017-0026-5

 

Abstract | Full Text

Platinum sensitivity in metastatic prostate cancer: does histology matter?

Michael S. Humeniuk, Rajan T. Gupta, Patrick Healy, Megan McNamara, Sundhar Ramalingam et al.

Prostate Cancer and Prostatic Diseases 2017 21 :92 - 99; December 11, 2017; 10.1038/s41391-017-0017-6

 

Abstract | Full Text

Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy

Mehmet Özsoy, Marco Moschini, Harun Fajkovic, Francesco Soria, Christian Seitz et al.

Prostate Cancer and Prostatic Diseases 2017 21 :100 - 105; December 11, 2017; 10.1038/s41391-017-0015-8

 

Abstract | Full Text

Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy

Daniel M. Moreira, Gerald L. Andriole, Ramiro Castro-Santamaria & Stephen J. Freedland

Prostate Cancer and Prostatic Diseases 2017 21 :106 - 112; December 04, 2017; 10.1038/s41391-017-0012-y

 

Abstract | Full Text

Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model

Ying-Chun Shen, Ali Ghasemzadeh, Christina M. Kochel, Thomas R. Nirschl, Brian J. Francica et al.

Prostate Cancer and Prostatic Diseases 2017 21 :113 - 125; December 04, 2017; 10.1038/s41391-017-0013-x

 

Abstract | Full Text

Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer

Benjamin Benzon, Stephanie A. Glavaris, Brian W. Simons, Robert M. Hughes, Kamyar Ghabili et al.

Prostate Cancer and Prostatic Diseases 2018 21 :126 - 136; March 20, 2018; 10.1038/s41391-018-0035-z

 

Abstract | Full Text

Overexpression of a (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells

Naseruddin Höti, Shuang Yang, Yingwei Hu, Punit Shah, Michael C. Haffner et al.

Prostate Cancer and Prostatic Diseases 2018 21 :137 - 146; January 16, 2018; 10.1038/s41391-017-0016-7

 

Abstract | Full Text

Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk

Yuanjun Ma & Nele Brusselaers

Prostate Cancer and Prostatic Diseases 2017 21 :147 - 152; December 19, 2017; 10.1038/s41391-017-0021-x

 

Abstract | Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Prostate Cancer and Prostatic Diseases. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature